Merck Stock Jumps 5% Following EU Approval for Bladder Cancer Therapy

Key Facts

In a move that strengthens the company's position in the global oncology market, Merck stock rose 5% to reach $121.75. This rally followed regulatory approval from European officials for a combination treatment involving Keytruda and Padcev. According to reports, the approval specifically covers the use of this therapy for a lower-risk form of bladder cancer.

This European approval comes amid intensifying competition in the oncology sector, where Merck competes with major peers such as Bristol-Myers Squibb and Roche. Keytruda remains Merck's primary revenue driver, with global sales reaching approximately $6.9 billion in Q1 2024 according to previous company earnings reports. Expanding its footprint in the European market is viewed as a critical catalyst for maintaining growth momentum ahead of looming patent expirations later this decade.

Investors should watch MRK price action, which stood at $121.75 (at close May 22, 2026), to see if it can sustain these gains. Looking at the upcoming calendar, while there are no immediate pharma-specific catalysts, broader Eurozone economic data scheduled for later this month may influence market sentiment for multinational corporations with significant European exposure.